Shares of Sunshine Biopharma, Inc. (SBFM) soared over 70% on Wednesday morning after the company announced positive results of mRNA therapy for cancer.
SBFM is currently trading at $3.5906, up $1.5006 or 71.4776%, on a huge volume of 36.5 million shares, above average volume of 71 thousand, on the Nasdaq. The stock opened its trading at $3.3000 after closing Tuesday at $2.0900. The stock has traded between $1.9000 and $248.0000 in the past 52-week period.
Sunshine Biopharma announced that it has completed additional studies on orthotopic human tumor models in mice confirming its K1.1 mRNA Lipid Nanoparticle (K1.1-mRNA-LNP) product as a novel therapeutic agent for human hepatocellular carcinoma.
Human hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide and the most common type of primary liver cancers in adults. In recent years, several treatment options were made available to HCC patients either as first-line or second-line treatment. Yet, the five-year survival rate of HCC patients remains at only 18-21%.
For comments and feedback: editorial@rttnews.com